Drug combination lifts breast cancer survival rates, study says
Aug 9, 2012
SEATTLE ― Women with metastatic breast cancer treated with a combination of two estrogen-blocking drugs survived more than six months longer than those treated with just one of the drugs or one followed by the other, according to a study involving nearly 700 women.It’s the first time such improvement in overall survival has been seen in trials of first-line hormonal therapy for hormone-receptive metastatic breast cancer, the study authors said.“We’re finding a lot of other ways of treating these